KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Accured Expenses: 2009-2025

Historic Change in Accured Expenses for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Sep 2025 value amounting to $126.3 million.

  • Jazz Pharmaceuticals' Change in Accured Expenses rose 147.49% to $126.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.7 million, marking a year-over-year decrease of 26.30%. This contributed to the annual value of $86.2 million for FY2024, which is 470.66% up from last year.
  • Jazz Pharmaceuticals' Change in Accured Expenses amounted to $126.3 million in Q3 2025, which was up 149.25% from -$256.4 million recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Change in Accured Expenses ranged from a high of $181.0 million in Q1 2025 and a low of -$256.4 million during Q2 2025.
  • Over the past 3 years, Jazz Pharmaceuticals' median Change in Accured Expenses value was $29.7 million (recorded in 2024), while the average stood at $10.3 million.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Change in Accured Expenses soared by 722.22% in 2021 and then crashed by 775.85% in 2025.
  • Jazz Pharmaceuticals' Change in Accured Expenses (Quarterly) stood at $48.8 million in 2021, then soared by 203.41% to $148.1 million in 2022, then slumped by 64.21% to $53.0 million in 2023, then crashed by 43.92% to $29.7 million in 2024, then soared by 147.49% to $126.3 million in 2025.
  • Its last three reported values are $126.3 million in Q3 2025, -$256.4 million for Q2 2025, and $181.0 million during Q1 2025.